Patents by Inventor Anton BENNETT

Anton BENNETT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and Compositions for Treating Fibrosis
    Publication number: 20230181588
    Abstract: The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Application
    Filed: October 18, 2022
    Publication date: June 15, 2023
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS
    Publication number: 20230036788
    Abstract: The present invention provides compositions and methods of inhibiting tyrosine phosphorylation. In one aspect, a composition comprising a low-dosage tyrosine kinase inhibitor, where the low-dosage tyrosine kinase inhibitor decreases tyrosine phosphorylation, is provided. In another aspect, a method for treating cardiovascular disease or condition associated with a RASopathy having aberrant protein tyrosine phosphorylation is described. Methods for treating congenital heart disease associated with Noonan or Noonan syndrome with multiple lentigines and decreasing aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation are also described.
    Type: Application
    Filed: August 30, 2022
    Publication date: February 2, 2023
    Inventors: Anton BENNETT, Jae-Sung YI
  • Compounds and compositions for treating fibrosis
    Patent number: 11504373
    Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 22, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • Compositions and methods of using tyrosine kinase inhibitors
    Patent number: 11458137
    Abstract: The present invention provides compositions and methods of inhibiting tyrosine phosphorylation. In one aspect, a composition comprising a low-dosage tyrosine kinase inhibitor, where the low-dosage tyrosine kinase inhibitor decreases tyrosine phosphorylation, is provided. In another aspect, a method for treating cardiovascular disease or condition associated with a RASopathy having aberrant protein tyrosine phosphorylation is described. Methods for treating congenital heart disease associated with Noonan or Noonan syndrome with multiple lentigines and decreasing aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation are also described.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: October 4, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Anton Bennett, Jae-Sung Yi
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS
    Publication number: 20220098214
    Abstract: The present invention provides compounds and methods for treating MKP5 modulated disease. In certain embodiments, the MKP5 modulated disease is a fibrotic disease.
    Type: Application
    Filed: January 30, 2020
    Publication date: March 31, 2022
    Inventors: Anton BENNETT, Gurulingappa HALLUR, Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY, Rama Kishore V.P. PUTTA
  • Compounds and Compositions for Treating Fibrosis
    Publication number: 20200390770
    Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 17, 2020
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS
    Publication number: 20200009142
    Abstract: The present invention provides compositions and methods of inhibiting tyrosine phosphorylation. In one aspect, a composition comprising a low-dosage tyrosine kinase inhibitor, where the low-dosage tyrosine kinase inhibitor decreases tyrosine phosphorylation, is provided. In another aspect, a method for treating cardiovascular disease or condition associated with a RASopathy having aberrant protein tyrosine phosphorylation is described. Methods for treating congenital heart disease associated with Noonan or Noonan syndrome with multiple lentigines and decreasing aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation are also described.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 9, 2020
    Inventors: Anton BENNETT, Jae-Sung YI
  • Compositions and methods of using tyrosine kinase inhibitors
    Patent number: 10471059
    Abstract: The present invention provides compositions and methods of inhibiting tyrosine phosphorylation. In one aspect, a composition comprising a low-dosage tyrosine kinase inhibitor, where the low-dosage tyrosine kinase inhibitor decreases tyrosine phosphorylation, is provided. In another aspect, a method for treating cardiovascular disease or condition associated with a RASopathy having aberrant protein tyrosine phosphorylation is described. Methods for treating congenital heart disease associated with Noonan or Noonan syndrome with multiple lentigines and decreasing aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation are also described.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: November 12, 2019
    Assignee: Yale University
    Inventors: Anton Bennett, Jae-Sung Yi
  • COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS
    Publication number: 20180271864
    Abstract: The present invention provides compositions and methods of inhibiting tyrosine phosphorylation. In one aspect, a composition comprising a low-dosage tyrosine kinase inhibitor, where the low-dosage tyrosine kinase inhibitor decreases tyrosine phosphorylation, is provided. In another aspect, a method for treating cardiovascular disease or condition associated with a RASopathy having aberrant protein tyrosine phosphorylation is described. Methods for treating congenital heart disease associated with Noonan or Noonan syndrome with multiple lentigines and decreasing aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation are also described.
    Type: Application
    Filed: January 26, 2016
    Publication date: September 27, 2018
    Inventors: Anton BENNETT, Jae-Sung YI